Leung BW, Wan G, Nguyen N, Rashdan H, et al. Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study. J Am Acad Dermatol 2023;88:1265-1270.
PMID: 36944564